In 110 patients aged ≥60 with newly diagnosed AML, eltrombopag from day 11 after induction chemotherapy did not improve overall survival vs placebo (HR 1.59; 95% CI 0.65–3.89; p=.31), but median platelet transfusions fell (8 vs 10) without more grade 3/4 adverse events.
RCTn = 110
Pigneux et al. Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG-2015 French Innovative Leukemia Organization phase 2 randomized trial